Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) shares dropped 1.6% during mid-day trading on Tuesday . The company traded as low as $5.00 and last traded at $5.00. Approximately 150 shares traded hands during mid-day trading, a decline of 100% from the average daily volume of 98,649 shares. The stock had previously closed at $5.08.
Innovent Biologics Stock Down 8.6 %
The business has a fifty day moving average price of $5.66 and a 200-day moving average price of $5.18.
Innovent Biologics Company Profile
Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.
Further Reading
- Five stocks we like better than Innovent Biologics
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- Insider Buying Explained: What Investors Need to Know
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- What is Put Option Volume?
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
